Emmaus Life Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Selected Financial Statement - Assets

Selected Financial Statement - Assets

9 Months Ended

Sep. 30, 2025

Balance Sheet Related Disclosures [Abstract]

Selected Financial Statement - Assets

NOTE 4 — SELECTED FINANCIAL STATEMENT — ASSETS

Inventories consisted of the following (in thousands):


	September 30, 2025			December 31, 2024
Raw materials and components	$	1,216		$	1,147
Work-in-process		44			184
Finished goods		5,027			5,328
Inventory reserve		(5,074	)		(5,024	)
Total inventories, net	$	1,213		$	1,635

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30, 2025		December 31, 2024
Prepaid insurance	$	200	$	622
Prepaid expenses		146		272
Other current assets		315		226
Total prepaid expenses and other current assets	$	661	$	1,120

Property and equipment consisted of the following (in thousands):


	September 30, 2025			December 31, 2024
Equipment	$	463		$	357
Leasehold improvements		16			15
Furniture and fixtures		30			30
Total property and equipment		509			402
Less: accumulated depreciation		(381	)		(356	)
Total property and equipment, net	$	128		$	46

For the three months ended September 30, 2025 and September 30, 2024, depreciation expense was approximately $15,000 and $5,000, respectively. For nine months ended September 30, 2025 and September 30, 2024, depreciation expense was approximately $24,000 and $17,000, respectively.